Results 91 to 100 of about 3,351 (178)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review

Blood and Lymphatic Cancer: Targets and Therapy, 2023
Nada Alsuhebany,1– 3 Congshan Pan,4 Eileen Holovac,5 Brian Do,6 Ali McBride7 1College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; 2King Abdulaziz Medical City, National Guard Health Affairs ...
Alsuhebany N, Pan C, Holovac E, Do B, McBride A   +4 more
doaj  

A Case of Radiation Recall Dermatitis From Zanubrutinib [PDF]

N
Thieman, Taylor
core   +2 more sources

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib [PDF]

Chronic lymphocytic leukemia (CLL) progression during Bruton tyrosine kinase (BTK) inhibitor treatment is typically characterized by emergent B-cell receptor pathway mutations.
Benrashid, Samon, Byrd, John C, de Bruin, Gerjan, De Jesus, Gary, Ghia, Paolo, Illés, Árpád, Jones, Daniel, Jurczak, Wojciech, Kater, Arnon P, Lai, Richard, Lai, Tzung-Huei, Long, Susan, Mohamed, Nehad, Munugalavadla, Veerendra, Robak, Tadeusz, Rule, Simon, Seymour, John F, Woyach, Jennifer A   +17 more
core   +1 more source

Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Clinical and Translational Medicine
Background CD19 chimeric antigen receptor (CAR) T‐cell therapy is a potential treatment for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL).
Rong Shen, Wei‐Guo Cao, Li Wang, Ling‐Shuang Sheng, Yi‐Lun Zhang, Wen Wu, Peng‐Peng Xu, Shu Cheng, Meng‐Ke Liu, Yan Dong, Yue Wang, Xiang‐Qin Weng, Xu‐Feng Jiang, Qi Song, Hong‐Mei Yi, Lei Li, Sheng Chen, Zi‐Xun Yan, Wei‐Li Zhao   +18 more
doaj   +1 more source

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia

Hematology Reports
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 ...
Samir Mouhssine, Nawar Maher, Sreekar Kogila, Claudio Cerchione, Giovanni Martinelli, Gianluca Gaidano   +5 more
doaj   +1 more source

EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma [PDF]

Mantle cell lymphoma (MCL) is a relatively rare B‐cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis.
Aurer, Igor, Campo, Elias, Cheah, Chan Y., Clark, Jonathan, Doorduijn, Jeanette, Dreyling, Martin, Eyre, Toby A., Fehr, Martin, Giné, Eva, Gomes da Silva, Maria, Jerkeman, Mats, Klener, Pavel, Ladetto, Marco, Network, the EHA Guidelines Committee and the European MCL, Ribrag, Vincent, Shpilberg, Ofer, Walewski, Jan   +16 more
core   +2 more sources

Updates on the Treatment of Richters Syndrome, Including Novel Combination Approaches. [PDF]

Richters syndrome (RS) or transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma (e.g., diffuse large B cell lymphoma, DLBCL) is a distinct disease that portends an overall poor prognosis and remains a challenge for ...
Heyman, Benjamin, Jain, Tanim
core   +1 more source

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Blood Advances
: Bruton tyrosine kinase inhibitors (BTKis) have led to changes in the treatment algorithm for patients with high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), defined based on the presence of genetic mutations.
Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, Alessandra Tedeschi, Constantine S. Tam   +10 more
doaj   +1 more source

Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia [PDF]

Matrix metalloproteinase-9 (MMP-9) facilitates the extravasation and lymphoid-tissue infiltration of chronic lymphocytic leukemia (CLL) cells. Prior studies found that high level expression of MMP-9 in CLL associates more aggressive disease. We find that
Ghia, Emanuela M, Hasan, Md Kamrul, Kipps, Thomas J, Widhopf II, George F   +3 more
core   +1 more source

Zanubrutinib

American Journal of Health-System Pharmacy, 2020
openaire   +2 more sources